Fred Hutch, Univ. of Washington biotech spinout Ensoma launches with $70M in funding
Dr. Hans-Peter Kiem of the Fred Hutchinson Cancer Research Center. (Fred Hutch Photo)
New spinout: Boston-based biotech startup Ensoma launched Thursday and announced a $70 million Series A funding round. The company is built on technology developed over two decades by Seattle researchers Dr. Hans-Peter Kiem of the Fred Hutchinson Cancer Research Center and Dr. André Lieber of the University of Washington School of Medicine.
Biotech strategy: The company’s Engenious vectors are designed to deliver gene therapies to patients without requiring stem cell donation or pre-treatments such as chemotherapy. The therapy can treat a variety of ailments including rare
This post was originally published on this site